Olaratumab (LY3012207)

olaratumab · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Olaratumab (LY3012207), covering 2020-09-10 to 2020-09-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma [Phase 1]

See pricing